SS Innovations announced that it has completed development of five new five-millimeter surgical instruments for use in pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.

The newly developed instruments include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps. The instruments are meant for use with the company’s SSi Mantra surgical robotic system.

“We developed several new smaller instruments designed to benefit critical surgical robotic procedures across multiple specialties, including pediatric, cardiac, and head and neck,” said SS Innovations CEO for Asia Pacific Dr. Vishwa Srivastava. “Our innovative 5-millimeter instruments, combined with our advanced, cost-effective SSi Mantra surgical robotic system, show great promise for supporting the large population of pediatric patients left behind each year. Globally, 1.7 billion children and adolescents lack easy access to critical surgical care, which can play a significant role in preventing disability and death. It has been reported that more than 390 million children under the age of five in lower- and middle-income countries do not receive timely intervention with safe and affordable surgical care. Unfortunately, to date most robotic surgeries have been geared towards the adult population. We aim to make robotic surgery more accessible to pediatric patients with new, smaller surgical instruments.”

“In addition, our 5-millimeter instruments can benefit cardiac surgery, which often involves small structures, such as the internal mammary artery during robotic coronary artery bypass surgery,” continued Dr. Srivastava. “Furthermore, our new robotic instruments can help perform critical tasks during head and neck procedures, which entail tight working space and quite small structures. Moving forward, we will continue to focus on developing differentiated surgical robotic technologies, such as these instruments, for the benefit of a larger segment of patients globally.”

As of 2025, SSi Mantra’s installed base totaled 168 systems, including 12 deployed across nine countries outside of India. To date, 153 hospitals have installed the surgical robot, and over 7,800 surgical procedures have been performed. This includes more than 120 telesurgeries and over 400 cardiac procedures.

Last month, the company submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the SSi Mantra robot for general, urological, colorectal, gynecological, and cardiac surgery.